Eko has raised a $41 million Series D funding round, bringing its total funding to $165 million. The new funds will be used to train AI algorithms to detect pulmonary conditions like asthma and pneumonia, and to expand the sale of its device and software to doctors outside the U.S. Despite Eko being the only company to integrate AI into a stethoscope, other startups like Ultromics and CardioSignal also use AI to detect heart conditions.
Key takeaways:
- Eko Health, a startup founded in 2013, is enhancing the traditional stethoscope with AI to help detect heart conditions more accurately and earlier.
- The company has sold its stethoscope to over 500,000 physicians and healthcare providers, amassing a large dataset of chest sounds and ECG information to develop algorithms for detecting heart conditions.
- In April, the Eko stethoscope received FDA clearance for using its AI to help detect the first signs of heart failure during a routine medical exam. This is the company's third algorithm to receive FDA approval.
- Eko has recently raised a $41 million Series D round, bringing its total funding to $165 million. The new funding will be used to train AI algorithms to detect pulmonary conditions and for selling its device and software to doctors outside of the U.S.